Stock AnalizTeva Pharmaceutical Industries (TEVA) earnings for the quarter ended September 2026: EPS beats estimates
Teva Pharmaceutical Industries reported results for the quarter ended September 2026 on November 3, 2026. Adjusted earnings per share came in at $0.86 against the analysts’ average forecast of $0.72, a beat of 19.3%.
Revenue for the quarter was $4.39 billion.
The market’s verdict: the stock rose 2.8% on the first trading day after the report.
The last four quarters
Teva Pharmaceutical Industries has beaten the analysts’ EPS forecast in 3 of the last 4 quarters.
| Quarter | EPS | Forecast | Surprise | Revenue growth | Price reaction |
|---|---|---|---|---|---|
| Sep 2026 | $0.86 | $0.72 | +19.3% | — | +2.8% |
| Jun 2026 | $0.00 | $0.05 | — | −1% | +0.0% |
| Mar 2026 | $0.50 | $0.49 | +2.0% | +2% | +0.0% |
| Dec 2025 | $0.93 | $0.63 | +47.6% | +11% | +0.0% |
What comes next
Analysts expect EPS of $0.67 for the next quarter on average and $2.06 for the fiscal year ending December 31, 2026.
The average analyst price target is $49.44, 11% above the current price of $44.50.
Valuation and score
Teva Pharmaceutical Industries scores 1.0 out of 5 overall on Stock Analiz (weak), trades at a trailing P/E of about 103.5, and its intrinsic value under moderate assumptions is about 86% below the current market value. Full Teva Pharmaceutical Industries analysis with 10 years of financials
Frequently asked questions
What was Teva Pharmaceutical Industries’s EPS for the quarter ended September 2026?
$0.86 adjusted per share, against an analyst consensus of $0.72.
How much revenue did Teva Pharmaceutical Industries report?
$4.39 billion.
More
This report was written automatically from the published numbers within hours of the release. It is information, not investment advice.